1. Home
  2. INDV vs ADPT Comparison

INDV vs ADPT Comparison

Compare INDV & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indivior PLC

INDV

Indivior PLC

N/A

Current Price

$35.53

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$25.90

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDV
ADPT
Founded
1994
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.5B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
INDV
ADPT
Price
$35.53
$25.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
9
Target Price
★ $49.00
$28.31
AVG Volume (30 Days)
1.3M
★ 2.4M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 8100.00
63.89
EPS
★ 1.67
N/A
Revenue
★ $1,239,000,000.00
$276,976,000.00
Revenue This Year
$7.50
$5.94
Revenue Next Year
$5.07
$22.42
P/E Ratio
$21.23
★ N/A
Revenue Growth
4.29
★ 54.77
52 Week Low
$23.55
$12.00
52 Week High
$42.81
$30.74

Technical Indicators

Market Signals
Indicator
INDV
ADPT
Relative Strength Index (RSI) 46.63 44.89
Support Level $33.45 $23.73
Resistance Level $35.54 $26.51
Average True Range (ATR) 0.96 1.43
MACD 0.10 -0.37
Stochastic Oscillator 38.21 12.46

Price Performance

Historical Comparison
INDV
ADPT

About INDV Indivior PLC

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: